-
Sodium Butyrate, HDAC3/c-Myc, and Liver Fibrosis
2026-08-28
This 2026 FASEB Journal study identifies an HDAC3/c-Myc-driven glycolytic program in hepatic stellate cells as a mechanistic target of gut-derived sodium butyrate. By combining computational target discovery with biochemical, cellular, and mouse validation, the work links microbial metabolite signaling to metabolic control of liver fibrosis and suggests testable anti-fibrotic strategies.
-
EdU Flow Cytometry Assay Kits (Cy5): Practical Guide
2026-08-27
EdU Flow Cytometry Assay Kits (Cy5) provide a denaturation-free approach to measuring DNA synthesis in S-phase cells by combining EdU incorporation with Cy5 click labeling. The assay is intended for validated flow cytometry workflows and should not be treated as standalone evidence of completed cell division or applied to fixed-paraffin tissues without separate validation.
-
IWR-1-endo: Wnt Signaling Inhibitor Workflow
2026-08-27
Build reproducible Wnt pathway experiments with IWR-1-endo, from DMSO stock preparation and dose-response design to β-catenin readouts and cell-type-aware validation. The workflow connects colorectal cancer research and regenerative biology with single-nucleus profiling principles while clearly separating established product evidence from practical assay recommendations.
-
AZD3463: A Mechanism-First ALK/IGF1R Guide
2026-08-26
AZD3463 is an ALK/IGF1R inhibitor with a distinctive evidence profile spanning biochemical kinase assays, neuroblastoma signaling, and combination treatment design. This guide explains how to interpret its potency, connect pathway inhibition with phenotype, and use the TSSK2 literature to strengthen assay decisions.
-
BATF2–ATF3 Signaling in Disc Degeneration
2026-08-26
A 2025 study identifies the BATF2–ATF3 axis as a mechanistic driver of intervertebral disc degeneration by linking transcriptional stress signaling to mitochondrial redox disruption in nucleus pulposus cells. Its overexpression, knockdown, and rescue experiments suggest that ATF3 is a potentially actionable mediator, while also defining important limits for translating this pathway into therapy.
-
μsPEF Myocardial Ablation and Mitochondrial Injury
2026-08-25
This study identifies mitochondrial dysfunction as a major secondary mechanism of cardiomyocyte death after microsecond pulsed electric field exposure, extending the mechanistic framework beyond irreversible electroporation. Its voltage- and pulse-dependent findings provide practical guidance for experimental ablation models while highlighting the need to distinguish metabolic activity, apoptosis, DNA synthesis, and tissue remodeling endpoints.
-
Myriocin, HIF-1, and Ferroptosis Resistance
2026-08-25
Liu et al. show that inhibiting de novo sphingolipid synthesis with myriocin protects HT22 neuronal cells from erastin- or glutamate-induced ferroptosis through HIF-1α activation, rather than by restoring intracellular glutathione. The study links myriocin to reduced HIF1A ubiquitination, altered glucose metabolism, and induction of HIF-1 effectors, providing a mechanistic framework for studying ferroptosis resistance in neurological models.
-
EdU Flow Cytometry Assay Kits (Cy5): Practical Guide
2026-08-24
This guide explains how to use EdU Flow Cytometry Assay Kits (Cy5) for flow-based measurement of DNA synthesis during S-phase, including reagent handling, controls, gating, and troubleshooting. The assay is suitable for non-denaturing proliferation measurements and multiplex flow cytometry, but should not be selected when DNA denaturation is required for epitope exposure or assay interpretation.
-
Bufalin–CRISPR Nanomedicine for CRC Immunotherapy
2026-08-24
The reference study introduces a calcium lactate nanoparticle that co-delivers bufalin and a CRISPR/Cas9 ribonucleoprotein targeting CD47 to combine tumor-cell killing with immune remodeling. Its proposed mechanism links pyroptosis, apoptosis, macrophage M1 repolarization, and enhanced phagocytosis, offering a multimodal strategy for colorectal cancer treatment while leaving important questions about dosing, delivery, and clinical translation.
-
Dabigatran Workflows for Thrombin Assays
2026-08-23
Build reproducible thrombin inhibition assays with Dabigatran, from concentration selection and plasma handling to PT, aPTT, and TT interpretation. This practical guide also shows how findings from berberrubine metabolomics research can sharpen assay selection without confusing pathway modulation with direct thrombin blockade.
-
BCAA Rheostat Restores Replicative HSC Fitness
2026-08-22
Bartram and colleagues show that accumulated HSC divisions produce metabolic, transcriptional, and functional drift rather than simply reducing stem-cell output. Their work identifies a shift in branched-chain amino acid use and demonstrates that replacing a BCAA transamination product can slow cell-cycle progression and restore more balanced hematopoietic regeneration.
-
EPZ-6438: Practical EZH2 Inhibitor Workflows
2026-08-21
EPZ-6438 gives researchers a selective way to connect EZH2 catalytic inhibition with H3K27me3 loss, transcriptional change, and cancer-cell phenotypes. This guide translates its use into reproducible dose–time studies, combination assays, malignant rhabdoid tumor models, lymphoma workflows, and melanoma resistance experiments.
-
Gαs-Selective G Protein Antagonists: NF 449
2026-08-20
The 1998 PNAS study identified NF 449 and NF503 as suramin analogues that preferentially inhibit Gαs activation and receptor coupling while sparing representative Gi/Go- and Gq-linked pathways. Its integrated nucleotide-binding, adenylyl cyclase, and receptor-coupling experiments established a framework for subtype-selective G protein inhibition and clarified why NF 449 should not be conflated automatically with later P2X1 or platelet applications.
-
Dinaciclib-VHL Synthetic Lethality in CC-RCC
2026-08-20
The reference study identifies a selective vulnerability in clear cell renal cell carcinoma: VHL-deficient tumors are unusually sensitive to the multi-cyclin-dependent kinase inhibitor Dinaciclib. Combining cell-based, molecular, and orthotopic patient-derived xenograft experiments, the authors show that Dinaciclib suppresses tumor growth while affecting both CD105-positive cancer stem cells and CD105-negative tumor cells.
-
EdU Imaging Kits (Cy5) for S-Phase Studies
2026-08-19
EdU Imaging Kits (Cy5) provide a morphology-preserving way to quantify DNA synthesis in adherent cells, tissue-derived cultures, and flow-cytometry samples. Their Cy5 click-chemistry readout is especially useful when proliferation must be separated from migration, apoptosis, or cell-cycle disruption in wound-healing and pharmacodynamic models.